Rebecca H. Boucher

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Peter Hillmen, Andy C. Rawstron, Kristian Brock et al. · Journal of Clinical Oncology · 2019 · 271 citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher et al. · Journal of Clinical Oncology · 2023 · 142 citations · Full text

Medicine, Hematology, Pharmacology +8

Targeted deep sequencing of urothelial bladder cancers and associated urinary <scp>DNA</scp> : a 23‐gene panel with utility for non‐invasive diagnosis and risk stratification

Douglas G. Ward, Naheema S. Gordon, Rebecca H. Boucher et al. · British Journal of Urology · 2019 · 60 citations · Full text

Medicine, Oncology, Urology +17

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

Niamh Appleby, Toby A. Eyre, Maité Cabes et al. · BMC Cancer · 2019 · 32 citations · Full text

Medicine, Hematology, Oncology +17

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, Rebecca H. Boucher, Nichola Webster et al. · Blood · 2020 · 18 citations

Medicine, Oncology, Pharmacotherapy +9